Affera Insights

Quarterly Performance Summary
Overall performance including deal closures, forecasts, and catheter utilization.

Deals Closed QTD

28

% to Plan (48 deals)

58%
Type 1
Type 2
Type 3
Prob. Adjusted Deal Forecast
52 deals

Above Target

Prob. Adjusted Revenue Forecast
$12.8M

Driven by catheter utilization

Weekly Sphere-9 Utilization vs. Target

Account TypeAvg. UtilizationTargetStatus
Overall6.29.0
Below Target
Type 13.17.0
Below Target
Type 26.89.0
Below Target
Type 310.510.0
On/Above Target
Pipeline Deep-Dive
Analysis of deal velocity, stage progression, and upsell opportunities.

Prob. Adjusted Deals in Pipeline: 24

Type 1
Type 2
Type 3
At-Risk Deals
2

Opportunities at risk of slipping past quarter end.

Pull-Forward Opportunities
1

Deals that could potentially close earlier.

Deal Breakdown

AccountStageStatusEst. Prob. to ConvertCurrent Close DateProjected Close Date
Sphere-9 Utilization Deep-Dive
Analysis of S9 catheter utilization, headroom, and performance against targets.

Accounts vs. Target Utilization

Type 1

1

Above Target

2

Below Target

Type 2

1

Above Target

2

Below Target

Type 3

3

Above Target

0

Below Target

Account Breakdown

AccountTerritory ReadinessTime to Steady StateProjected UpsideActual vs. Target Utilization
Apex Health
Type 1
New England
8 weeks
28%

7.5

vs 7.0 target

Noble Health
Type 1
Texas
12 weeks
15%

2.1

vs 7.0 target

Trinity Wellness
Type 1
SoCal
10 weeks
22%

3.5

vs 7.0 target

Vertex Healthcare
Type 2
Midwest
6 weeks
18%

9.2

vs 9.0 target

Legacy Health System
Type 2
Florida
9 weeks
12%

5.9

vs 9.0 target

Synergy Medical
Type 2
NY
4 weeks
25%

8.5

vs 9.0 target

Pinnacle Health
Type 3
Carolinas
3 weeks
10%

10.1

vs 10.0 target

Progressive Care
Type 3
Ohio Valley
5 weeks
14%

10.8

vs 10.0 target

Frontier Health
Type 3
Mountain
4 weeks
16%

11.2

vs 10.0 target

Deal Velocity by Account Type
Comparison of historical vs. projected average deal cycle time (in days), with high-low range.